Global /United States /Healthcare /Biotechnology /NGNE

Neurogene Inc.

NGNE

• NASDAQ: NGNE • Delayed

26.48USD -3.5%

As of 13 June 2026, Neurogene Inc. has a market cap of $413.51M USD, ranking #16443 globally and #2775 in the United States. It ranks #1485 in the Healthcare sector, and #289 in the Biotechnology industry.

Global Rank

16443

Country Rank

2775

Sector Rank

1485

Industry Rank

289

Key Stats

Market Cap

$413.51MUSD

Enterprise Value

$153.45MUSD

EBITDA (TTM)

-$100.12MUSD

Net Income (TTM)

-$90.35MUSD

PB Ratio

1.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Rachel McMinn open_in_new

Employees

131

Founded

2003

Website

neurogene.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.5%	-0.5%	30%	37%	-15%	28%	82%	87%	-86%

News

NGNE Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	NGNE Neurogene Inc ISIN: US64135M1053 Shares Out.: Shares Outstanding: 15.802M¹ Shares Float: 12.531M² TV: TradingView: NASDAQ: NGNE SA: Stock Analysis: NASDAQ: NGNE YF: Yahoo Finance: NGNE GF: Google Finance: NASDAQ: NGNE NQ: NASDAQ: NGNE BA: Barron's: NGNE MS: Morningstar: XNAS: NGNE	26.48 USD	TV: TradingView: NASDAQ: NGNE SA: Stock Analysis: NASDAQ: NGNE YF: Yahoo Finance: NGNE GF: Google Finance: NASDAQ: NGNE NQ: NASDAQ: NGNE BA: Barron's: NGNE MS: Morningstar: XNAS: NGNE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Neurogene Inc.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 44K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 39K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 7K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 6K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 6K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 4K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 11K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 11K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 10K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 10K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 7K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 6K%	-	Germany

chevron_leftBack